SBRT and Durvalumab for Inoperable/Unresectable Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2024-12-31
Target enrollment:
Participant gender:
Summary
The investigators propose a phase II single-arm study on using stereotactic body radiation
therapy in combination with durvalumab for inoperable/unresectable hepatocellular carcinoma.
In addition, the investigators will also measure the change in number and intensity of
PD-L1-positive circulating tumor cells before and after stereotactic body radiation therapy
and durvalumab and evaluate their correlation with treatment response.